<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35717769</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J Clin Virol</ISOAbbreviation></Journal><ArticleTitle>The circulation of Non-SARS-CoV-2 respiratory viruses and coinfections with SARS-CoV-2 during the surge of the Omicron variant.</ArticleTitle><Pagination><StartPage>105215</StartPage><MedlinePgn>105215</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2022.105215</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(22)00148-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">In December 2021, the SARS-CoV-2 Omicron variant displaced the Delta variant and caused an unprecedented spike in the numbers of COVID-19 cases. This study reports the positivity rates of circulating non-SARS-CoV-2 respiratory viruses and evaluates coinfections of these viruses with SARS-CoV-2 during the Omicron surge.</AbstractText><AbstractText Label="METHODS">Data from the multiplex respiratory panels used for diagnosis at the Johns Hopkins Microbiology Laboratory were used to assess positivity rates and respiratory virus coinfections in the time frame between November 2021 and February 2022. Clinical presentations and outcomes were assessed in the cohort of 46 patients who had SARS-CoV-2 coinfections with other respiratory viruses.</AbstractText><AbstractText Label="RESULTS">Between November 2021 and February 2022, the high positivity of SARS-CoV-2 outcompeted enterovirus/rhinovirus and other circulating respiratory viruses and was associated with a notable decrease in influenza A infections. Coinfections represented 2.3% of the samples tested by the extended multiplex respiratory panel. SARS-COV-2 coinfections represented 25% of the coinfections in this time frame and were mostly SARS-COV-2/enterovirus/rhinovirus. Of the SARS-CoV-2 coinfection cohort, 3 patients were hospitalized and were coinfected with influenza-A (2) or RSV (1). Cough and shortness of breath were the most frequent symptoms (29%) followed by fever (28%).</AbstractText><AbstractText Label="CONCLUSIONS">The SARS-CoV-2 Omicron surge was associated with a change in the circulation of other respiratory viruses. Coinfections were most prevalent with viruses that showed the highest positivity in this time frame.</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eldesouki</LastName><ForeName>Raghda E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Meyer B-121F, 600 North Wolfe Street, Baltimore, MD, 21287-7093, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhteg</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Johns Hopkins Hospital Medical Microbiology Laboratory, Meyer B-130, 600 North Wolfe Street, Baltimore, MD, 21287-7093, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Heba H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Meyer B-121F, 600 North Wolfe Street, Baltimore, MD, 21287-7093, United States of America. Electronic address: hmostaf2@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coinfection</Keyword><Keyword MajorTopicYN="N">Enterovirus/ rhinovirus</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Respiratory viruses</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>19</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35717769</ArticleId><ArticleId IdType="pmc">PMC9174098</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2022.105215</ArticleId><ArticleId IdType="pii">S1386-6532(22)00148-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen J., Wang R., Gilby N.B., Wei G.W. Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. ArXiv. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannan S., Shaik Syed Ali P., Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur. Rev. Med. Pharmacol. Sci. 2021;25(24):8019–8022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982466</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E., Ntoumi F., Hui D.S., et al. Emergence of new SARS-CoV-2 variant of concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int. J. Infect. Dis. 2022;114:268–272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634699</ArticleId><ArticleId IdType="pubmed">34863925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A., Eldesouki R.E., Sachithanandham J., et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: an investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022;79</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020587</ArticleId><ArticleId IdType="pubmed">35460989</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhteg K., Amadi A., Forman M., Mostafa H.H. Circulation of non- SARS-CoV-2 respiratory pathogens and coinfection with SARS-CoV-2 amid the COVID-19 pandemic. Open Forum Infect. Dis. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863080</ArticleId><ArticleId IdType="pubmed">35211632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa H.H., Carroll K.C., Hicken R., et al. Multi-center evaluation of the Cepheid Xpert(R) Xpress SARS-CoV-2/Flu/RSV Test. J. Clin. Microbiol. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383535</ArticleId><ArticleId IdType="pubmed">32366669</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J., Uhteg K., Forman M.S., et al. Clinical performance of the GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract infections. J. Clin. Virol. 2021;135</Citation><ArticleIdList><ArticleId IdType="pubmed">33497932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A., Eldesouki R.E., Sachithanandham J., et al. A quick displacement of the SARS-CoV-2 variant Delta with Omicron: unprecedented spike in COVID-19 cases associated with fewer admissions and comparable upper respiratory viral loads. medRxiv. 2022 2022.01.26.22269927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020587</ArticleId><ArticleId IdType="pubmed">35460989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr. Opin. Pediatr. 2016;28(1):107–113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Zhang T., Lyu Y., et al. Influenza's plummeting during the COVID-19 pandemic: the roles of mask-wearing, mobility change, and SARS-CoV-2 interference. Engineering (Beijing) 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808434</ArticleId><ArticleId IdType="pubmed">35127196</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann P.J., Nakajima N., Sato Y., et al. SARS-CoV-2 interference of influenza virus replication in Syrian hamsters. J. Infect. Dis. 2021;225(2):282–286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689717</ArticleId><ArticleId IdType="pubmed">34875072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>